Dermatomycoses Market to Grow at a Substantial Growth Rate During the Forecast Period (2019-2032) – DelveInsight | Key Companies – Novan, Blueberry Therapeutics, and many others

June 30 16:10 2022
Dermatomycoses Market to Grow at a Substantial Growth Rate During the Forecast Period (2019-2032) -  DelveInsight | Key Companies - Novan, Blueberry Therapeutics, and many others
Delveinsight Business Research LLP

DelveInsight’s “Dermatomycoses Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Dermatomycoses Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Dermatomycoses market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Dermatomycoses Market

Dermatomycoses: An Overview

Dermatomycoses is the medical term for fungal infections of the skin and skin appendages ―which encompass nails and hair―caused most commonly by dermatophytes. Fungal infections can happen at any time, and it can be caused due to injured or pathologically changed skin areas.

Dermatomycoses Market Key Facts

  • As per the Nenoff et al. (2013), around 91% of the anthropophilic fungus, i.e., T. rubrum, among the dermatophytes caused tinea unguium in Germany.

  • According to the Shimoyama et al. (2019), in dermatophytosis, tinea pedis was the most frequent type, followed by tinea unguium (57.4%), tinea corporis (28.3%); tinea cruris (7.3%); tinea manuum (1%); tinea capitus, Celsus’ kerion (0.5%); and tinea barbae (0.02%).

  • As per Mochizuki et al. (2019), dermatomycoses, including dermatophytosis, is commonly encountered in routine medical care. In Japan, 21.6% of the population was estimated to have tinea pedis, while 10.0% were estimated to have tinea unguium.

Dermatomycoses Market

The Dermatomycoses market dynamics are anticipated to change in the coming years due to improved diagnosis methodologies, raising awareness of the diseases, incremental healthcare spending across the world, and the expected launch of emerging therapies.

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Dermatomycoses market size by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete detail of the Dermatomycoses market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, mechanism of action (MoA), competition with other therapies, brand value, and their impact on the market.

Dermatomycoses Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of diagnosed patient pool and future trends.

Dermatomycoses Epidemiology Segmentation

  • Total cases of Dermatomycoses

  • Total Incidence/Prevalence of Disease-causing Dermatomycoses

  • Diagnosed and treatable cases of Dermatomycoses

Dermatomycoses Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Dermatomycoses market or expected to get launched during the study period. The analysis covers Dermatomycoses market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Dermatomycoses Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Request for Sample PDF Report –

Dermatomycoses Therapeutics Analysis

Increased awareness of this unique histology has allowed the development of drugs that are specific to dermatomycoses and has begun to shed light on the similarities and possible unique aspects.

Currently, several key companies are developing therapies for the treatment of Dermatomycoses.  The launch of the emerging therapies is expected to create a significant shift in the market size. 

Some of the key companies in the Dermatomycoses Market include:

  • Novan

  • Blueberry Therapeutics

And many others

Dermatomycoses Therapies covered in the report include:

  • BB2603BB2603 is being developed by Blueberry Therapeutics which is a first-in-class nano-formulation of the most effective antifungal agent in the market currently. It is designed to treat both onychomycosis and Tinea pedis simultaneously.

  • SB208Novan is developing SB208 as a broad-spectrum antifungal gel to treat superficial cutaneous fungal infections of the skin and nails.

And many more

Get More Detailed Insights Into the Emerging Therapies & Key Companies –

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Dermatomycoses Competitive Intelligence Analysis

4. Dermatomycoses Market Overview at a Glance

5. Dermatomycoses Disease Background and Overview

6. Dermatomycoses Patient Journey

7. Dermatomycoses Epidemiology and Patient Population

8. Dermatomycoses Treatment Algorithm, Current Treatment, and Medical Practices

9. Dermatomycoses Unmet Needs

10. Key Endpoints of Dermatomycoses Treatment

11. Dermatomycoses Marketed Products

12. Dermatomycoses Emerging Therapies

13. Dermatomycoses Seven Major Market Analysis

14. Attribute Analysis

15. Dermatomycoses Market Outlook (7 major markets)

16. Dermatomycoses Access and Reimbursement Overview

17. KOL Views on the Dermatomycoses Market.

18. Dermatomycoses Market Drivers

19. Dermatomycoses Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report –

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.


Other Trending Healthcare Reports by DelveInsight

Implantable Cardioverter Defibrillators (ICDs) Market
“Implantable Cardioverter Defibrillators (ICDs) Market” research report delivers an in-depth understanding of the Implantable Cardioverter Defibrillators market size, share, and trends as well as the potential emerging products and key companies operating in the market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States